In certain types of cancers, an objective response has been observed, including for KRASG12C inhibitors AMG510 and MRTX849 in KRASG12C-mutant lung or colorectal cancer patients, for the SRC homology-2-containing protein tyrosine phosphatase 2 (SHP2) inhibitor RMC-4630 in advanced NSCLC patients harboring KRAS mutation and for RAS/MEK inhibitor RO5126766 (VS-6766) combination with FAK inhibitor in KRAS mutation low-grade serous ovarian cancer (LGSOC) [15–17]. This evidence concerns the gene KRAS and cancer.